|
|
|
|
|
|
|
|
|
|
|
05.03.26 - 11:24
|
Affinia receives FDA fast track designation for AFTX-201 (PBR)
|
|
|
AFTX-201 is being evaluated as a one-time intravenous gene therapy in adults with genetically confirmed BAG3 DCM. The therapy delivers a fully human, full-length BAG3 transgene using the
The post Affinia receives FDA fast track designation for AFTX-201 appeared first on Pharmaceutical Business review....
|
|
|
|
|
29.01.26 - 13:03
|
Demeetra Completes Acquisition of Hera BioLabs, Securing Expanded Rights to Hyperactive Super piggyBac® Transposase (Business Wire)
|
|
|
LEXINGTON, Ky.--(BUSINESS WIRE)--#Biomanufacturing--Demeetra AgBio, a genome engineering company enabling research and biomanufacturing through advanced gene-editing technologies and engineered CHO host cells, announced the completion and full integration of its acquisition of Hera BioLabs. The transaction, completed June 1, resulted in Demeetra now holding expanded rights to the hyperactive Super piggyBac® transposase platform and technologies, establishing Demeetra as the definitive commercial source for licensing and access across broad fields of use.
Super piggyBac is a proprietary, non-viral transposase platform developed through protein engineering and protected by U.S. and international patents and trademarks. The platform delivers higher integration efficiency and increased transgene copy number compared to wild-type piggyBac, while preserving piggyBac's large cargo capacity and favorable integration profile. In direct performance comparisons, Super piggyBac demonstrates performance comparable t...
|
|
|
|
|
|
|
17.12.25 - 17:48
|
Transgene to Participate in Upcoming Investor Meetings (GlobeNewswire EN)
|
|
|
Strasbourg (France), December 17, 2025, 17:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors during the upcoming editions of:...
|
|
|
27.11.25 - 14:36
|
XFRA: TGNA: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
TRANSGENE SA EO 0,30 TGNA FR0005175080
AB/FROM ONWARDS 27.11.2025 14:21 CET...
|
|
|
|
|
|
|
26.11.25 - 09:48
|
XFRA: TGNA: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
TRANSGENE SA EO 0,30 TGNA FR0005175080 BAW/UFN...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
